干擾素:生物相似藥的洞察(2020年)

干擾素，是對幾個病毒的存在作出反應，由宿主細胞製作，傳達放出的訊號的蛋白質群組。典型性的情況下，感染病毒的細胞會放出干擾素，成為周圍的細胞提高抗病毒防禦力的原因。干擾素還分類為其亞種。

本報告提供干擾素的相關調查，藥物概要，生物相似藥法規預測，研究開發，機會，市場成長及阻礙因素，主要企業的簡介等資訊。

目錄

第1章 主要洞察

第2章 概述

第3章 摘要整理

第4章 生物相似藥的法規

• 北美
  • 美國
  • 加拿大
• 歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲
• 其他地區
  • 巴西
  • 墨西哥
  • 阿根廷
  • 沙烏地阿拉伯

第5章 干擾素(參照產品:Avonex)

• 藥物簡介
• 產品概要
• 法規核准與發售
• 適應症
• 作用機制
• 投藥和管理
• 劑量和優勢
• 輻射劑量變更
• 合成的路徑
• 藥理學
• 藥效學
• 藥物動力學
• 有害反應
• 產品的概述
• 開發里程碑

第6章 研究開發

• 臨床試驗資訊
• 安全性和有效性

第7章 Avonex生物相似藥:新機會

第8章 生物相似藥的評估

• 各產品類型評估
• 各給藥途徑評估
• 各分子類型評估
• 銷售核定

第9章 企業簡介

• Zydus Cadila
• Profarma

第10章 比較形勢:各企業

第11章 競爭情形

• 概況
• 市場佔有率分析
• 競爭模式

第12章 市場成長要素

第13章 市場障礙

第14章 SWOT分析

第15章 附錄

第16章 參考文件

第17章 DelveInsight的服務內容

第18章 免責聲明

第19章 關於DelveInsight

DelveInsight's , "Interferon- Biosimilar Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Interferon Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Interferon Understanding

Interferon: Overview

Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses. Interferon is further categorized in its variants.

Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli in the laboratory of Charles Weissmann at the University of Zurich, in 1980.

Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis. It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some claims have been made that Interferons produce about an 18-38% reduction in the rate of MS relapses.

Interferon Biosimilars: Drugs Chapters

This segment of the Interferon report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interferon Biosimilars: Marketed Drugs

• Bioferon: Biosidus

Bioferon is being developed by Biosidus. The drug is being approved for the treatment of Cancer; Hepatitis B; Hepatitis C; Kaposi's sarcoma.

Further product details are provided in the report.

Interferon Biosimilars: Emerging Drugs

• Interferon beta-1b biosimilar: Harvest Moon Pharmaceuticals

Harvest Moon Pharmaceuticals is developing Interferon beta-1b biosimilar for the treatment of Multiple sclerosis.

Further product details are provided in the report.

Interferon: Therapeutic Assessment

This segment of the report provides insights about the different Interferon biosimilars segregated based on following parameters that define the scope of the report, such as:

• Major Players in Interferon

There are approx. 10+ key companies which are developing the therapies for Interferon.

• Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

• Marketed stage products
• Late stage products (BLA Filed and Phase III)
• Mid-stage products (Phase II and
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Interferon pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibodies
• Peptide
• Protein
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interferon: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Interferon biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interferon biosimilar drugs.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Interferon R&D. The therapies under development are focused on novel approaches to treat/improve Interferon.

Interferon Biosimilars Report Insights

• Interferon Biosimilar Pipeline Analysis
• Therapeutic Assessment
• Sales Assessment
• Unmet Needs
• Impact of Drugs

Interferon Biosimilar Report Assessment

• Marketed Product profiles
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Sales Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Interferon Biosimilars?
• How many Interferon biosimilars are developed by each company?
• How many emerging biosimilars are in mid-stage, and late-stage?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Interferon biosimilars therapeutics?
• What are the clinical studies going on for Interferon biosimilars and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Zydus Cadila
• Reliance Life Sciences
• Profarma
• Harvest Moon Pharmaceuticals
• Dong-A ST
• CinnaGen
• BioPartners
• Biocad
• Amega Biotech

Key Products

• MAB 2
• ReliBeta
• PF-08
• Interferon beta-1b biosimilar
• DA-3051
• Cinno Vex
• ReciGen
• Bioferon
• Inmutag
• Alpheon
• BCD-033
• Megavex

 

Table of Contents

1. Key Insights

2. Interferon Biosimilars: Snapshot

3. Executive Summary

• 3.1. Overview
• 3.2. The Basics of Biologics.
• 3.3. Biosimilars are not the Same as Generic Drugs
• 3.4. Economics of Biosimilars - the Promise of Lower Prices, but at What Cost?
• 3.5. What Patients Need to Know About Biosimilars

4. Regulatory Outlook For Biosimilars

• 4.1. North America
  • 4.1.1. US
  • 4.1.2. Canada
• 4.2. Europe
• 4.3. Asia Pacific
  • 4.3.1. China
  • 4.3.2. India
  • 4.3.3. Japan
  • 4.3.4. South Korea
  • 4.3.5. Australia
• 4.4. Rest Of The World
  • 4.4.1. Brazil
  • 4.4.2. Mexico
  • 4.4.3. Argentina
  • 4.4.4. Saudi Arabia

More Countries would be added in the final report

5. Interferon (Reference Product: Avonex)

• 5.1. Drug Profile
• 5.2. Product Overview
• 5.3. Regulatory Approvals and Launch
• 5.4. Indications
• 5.5. Mechanism of Action
• 5.6. Dosage and Administration
• 5.7. Dosage and Strengths
• 5.8. Dose Modification
• 5.9. Route of Synthesis
• 5.10. Pharmacology
• 5.11. Pharmacodynamics
• 5.12. Pharmacokinetics
• 5.13. Adverse Reactions
• 5.14. Product Snapshot
• 5.15. Development Milestones

6. Research and Development

• 6.1. Clinical Trials Information
• 6.2. Safety and Efficacy

7. Avonex Biosimilar: Emerging Opportunities

More variants of Interferon would be added in the final report

8. Interferon: Biosimilars Assessment

• 8.1. Assessment by Product Type
• 8.2. Assessment by Route of Administration
• 8.3. Assessment by Molecule type
• 8.4. Sales Assessment

9. Interferon Biosimilars Profiles: By Company

• 9.1.1. Zydus Cadila
  • 9.1.1.1. MAB 2: Zydus Cadila
  • 9.1.1.1.1. Product Information
  • 9.1.1.1.2. Research and Development
  • 9.1.1.1.3. Other Development Activities
  • 9.1.1.1.4. General Description Table
• 9.1.2. Profarma
  • 9.1.2.1. PF-08: Profarma
  • 9.1.2.1.1. Product Information
  • 9.1.2.1.2. Research and Development
  • 9.1.2.1.3. Other Development Activities
  • 9.1.2.1.4. General Description Table

More Companies and products would be added in the final report

10. Interferon Biosimilars: Comparative Landscape: By Company

11. Interferon Biosimilars: Competitive Landscape

• 11.1.1. Overview
• 11.1.2. Market Share Analysis
• 11.1.3. Competitive Scenario
  • 11.1.3.1. Product Launches and approval
  • 11.1.3.2. Partnerships, Collaborations and Agreements
  • 11.1.3.3. Acquisitions
  • 11.1.3.4. Expansions
  • 11.1.3.5. Patent Expiration of Biologics

More information would be added in the final report

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix

• 15.1. Research Methodology
  • 15.1.1. Coverage
  • 15.1.2. Secondary Research

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

• Table 1 Total Products for Interferon
• Table 2 Late Stage Products
• Table 3 Mid Stage Products
• Table 4 Early Stage Products
• Table 5 Pre-clinical & Discovery Stage Products
• Table 6 Assessment by Product Type
• Table 7 Assessment by Stage and Product Type
• Table 8 Assessment by Route of Administration
• Table 9 Assessment by Stage and Route of Administration
• Table 10 Assessment by Molecule Type
• Table 11 Assessment by Stage and Molecule Type
• Table 12 Inactive Products

List of Figures

• Figure 1 Total Products for Interferon
• Figure 2 Late Stage Products
• Figure 3 Mid Stage Products
• Figure 4 Early Stage Products
• Figure 5 Preclinical and Discovery Stage Products
• Figure 6 Assessment by Product Type
• Figure 7 Assessment by Stage and Product Type
• Figure 8 Assessment by Route of Administration
• Figure 9 Assessment by Stage and Route of Administration
• Figure 10 Assessment by Molecule Type
• Figure 11 Assessment by Stage and Molecule Type
• Figure 12 Inactive Products